Shifting Frontiers: The Expansion of Cell & Gene Therapies into Autoimmune Disease  | Allucent

Shifting Frontiers: The Expansion of Cell & Gene Therapies into Autoimmune Disease 

The Expansion of Cell & Gene Therapies into Autoimmune Disease 

Cell and gene therapies (CGTs) are ushering in a new era of innovation in medicine that extends well beyond oncology into the treatment of autoimmune diseases. This infographic, Shifting Frontiers: The Expansion of Cell & Gene Therapies into Autoimmune Disease, visualizes the expanding role of CGTs in addressing over 80 chronic autoimmune conditions that have traditionally relied on symptom management, broad immunosuppression, and chronic care. 

Building on the clinical success of CAR T-cell therapies in hematologic cancers, researchers are now exploring advanced immunomodulatory approaches such as regulatory T-cells (Tregs), B-cell CGTs, and in vivo gene editing to reprogram the immune system and potentially restore long-term immune tolerance. The infographic highlights strong industry momentum, with over $609M in Q4 2024 early-stage investments and 43 FDA-approved CGT products by the end of that year, seven of which were non-oncology indications. 

By shifting the therapeutic goal from disease management to long-term remission or even cure, CGTs are poised to reshape the future of autoimmune care—offering new hope to millions worldwide. 

Get the Full Infographic: Explore the Future of Cell & Gene Therapy in Autoimmune Disease

To view the gated content, please fill out the form below.

Featured Content

Partner With the A-Team

Let us know how we can help you bring new therapies to light. Get in touch to get started.

Join the A-Team

Want to help small and mid-sized biotech companies change the therapeutic landscape?

Subscribe to our monthly newsletter